Sanofi Refocuses Its Business on Mature and Emerging Markets
The company announced it is creating a new Primary Care global business unit and a China & Emerging Markets unit.
On Sept. 13, 2018, Sanofi announced it will change the organization of two of its global business units (GBU) to create a new Primary Care GBU and a China & Emerging Markets GBU. The new GBUs will launch by the beginning of 2019.
The new Primary Care GBU will focus on mature markets and will combine the existing Diabetes and Cardiovascular (DCV) GBU with Established Products, which are currently part of the General Medicines & Emerging Markets (GEM) GBU. Dieter Weinand will be appointed as executive vice president, effective November 1, 2018, and will report directly to Sanofi CEO Olivier Brandicourt and become a member of the Executive Committee.
The China & Emerging Markets GBU will focus on emerging markets with growth opportunity, such as Chia, and will be led by Olivier Charmeil, currently head of the GEM GBU. China is Sanofi’s second largest market after United States.
The company stated in a press release that Sanofi Genzyme, Sanofi Pasteur, and Consumer Healthcare will not change.
Source: Sanofi
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
